Register Login
Register to leave comments
  • News bot Aug. 13, 2026, 8:05 p.m.

    📋 AKTIS ONCOLOGY, INC. (AKTS) - Financial Results

    Filing Date: 2026-08-13

    Accepted: 2026-08-13 16:04:16

    Event Type: Financial Results

    Event Details:

    AKTIS ONCOLOGY, INC. (AKTS) Reports the reporting period Financial Results AKTIS ONCOLOGY, INC. (AKTS) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: 3384
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 517320
      • human clinical imaging and dosimetry data for AKY
      • 2519, supporting a broad clinical development program in patients with prostate, lung, and other B7
      • H3 expressing solid tumors
        • targeting Nectin-4, with multi-indication potential across multiple tumor types, including locally advanced or metastatic urothelial cancer, breast cancer, and other solid tumor cancers. Aktis’ second clinical-stage pipeline program, AKY-2519
        • targeting B7-H3 expressing tumors, including prostate, lung, and other solid tumors. Aktis has a discovery collaboration with Eli Lilly and Company to leverage Aktis’ miniprotein platform to develop novel radioconjugates outside of its proprietary pipeline. For more information, please visit www.aktisoncology.com. Forward-looking statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2026 2025 Change ($) Change (%)
    Operating Expenses Loss From Operations 20.96K 51.60K $-30.64K -59.38%
    Other Income Expense Interest Income 2.91K 9.15K $-6.24K -68.22%
    Other Income Expense Net Loss 18.07K 42.47K $-24.39K -57.44%
    Cash Equivalents Marketable Securities 517.32K 226.79K $290.53K +128.11%
    Revenue 3.38K 1.60K $1.78K +111.37%
    Loss from Operations 28.90K 20.96K $7.94K +37.86%
    Interest Income 4.76K 2.91K $1.86K +63.86%
    Other Income, Net 4.75K 2.89K $1.87K +64.65%
    Net Loss 24.14K 18.07K $6.07K +33.58%
    Cash and Marketable Securities 517.32K 226.79K $290.53K +128.11%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: AKTIS ONCOLOGY, INC.
    • Ticker Symbol: AKTS

Search

News categories